| Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes (NCT01357252) | Novartis Pharmaceuticals | 2011-04-01 |
| Efficacy of Diclofenac Potassium vs Nimesulide in the Treatment of Fever and Pain in Children With Upper Respiratory Tract Infection (NCT01257126) | Novartis Pharmaceuticals | 2011-04-01 |
| Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients (NCT01275196) | Novartis Pharmaceuticals | 2011-04-01 |
| Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder (NCT01338818) | Novartis Pharmaceuticals | 2011-04-01 |
| A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors (NCT01240655) | Novartis Pharmaceuticals | 2011-04-01 |
| Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients (NCT01348100) | Novartis Pharmaceuticals | 2011-04-01 |
| Safety and Efficacy of LCI699 in Cushing's Disease Patients (NCT01331239) | Novartis Pharmaceuticals | 2011-03-23 |
| Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept (NCT01379508) | Novartis Pharmaceuticals | 2011-03-21 |
| PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function (NCT01429337) | Novartis Pharmaceuticals | 2011-03-07 |
| Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects (NCT01459250) | Novartis Pharmaceuticals | 2011-03-01 |
| ACZ885 in Type 1 Diabetes Mellitus (NCT01322321) | Novartis Pharmaceuticals | 2011-03-01 |
| 12-week Open-label Evaluation of Efficacy and Safety of Indacaterol (NCT01232894) | Novartis Pharmaceuticals | 2011-03-01 |
| Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis (NCT01327664) | Novartis Pharmaceuticals | 2011-03-01 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects (NCT01596712) | Novartis Pharmaceuticals | 2011-03-01 |
| Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children (NCT01328886) | Novartis Pharmaceuticals | 2011-03-01 |
| Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers (NCT01353508) | Novartis Pharmaceuticals | 2011-03-01 |
| Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma (NCT01223027) | Novartis Pharmaceuticals | 2011-03-01 |
| Safety and Tolerability of BVS857 in Subjects With Insulin Resistance (NCT01435330) | Novartis Pharmaceuticals | 2011-03-01 |
| Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (NCT01318941) | Novartis Pharmaceuticals | 2011-03-01 |
| Canakinumab in Patients With Active Hyper-IgD Syndrome (NCT01303380) | Novartis Pharmaceuticals | 2011-03-01 |
| Assess Increased Mortality Risk With Each Year of Delayed Tobramycin Solution (TIS) Initiation, and Effect of TIS on Mortality Across Study Centers (NCT01460849) | Novartis Pharmaceuticals | 2011-03-01 |
| QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT01315249) | Novartis Pharmaceuticals | 2011-03-01 |
| A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica (NCT01364389) | Novartis Pharmaceuticals | 2011-02-14 |
| Pharmacokinetics of AGO178 in Participants With Liver Impairment (NCT01531309) | Novartis Pharmaceuticals | 2011-02-08 |
| BKM120 as Second-line Therapy for Advanced Endometrial Cancer (NCT01289041) | Novartis Pharmaceuticals | 2011-02-01 |
| A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema (NCT01315275) | Novartis Pharmaceuticals | 2011-02-01 |
| Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis (NCT01310166) | Novartis Pharmaceuticals | 2011-02-01 |
| Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus (NCT01294774) | Novartis Pharmaceuticals | 2011-02-01 |
| Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes (NCT01309698) | Novartis Pharmaceuticals | 2011-02-01 |
| Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT01294787) | Novartis Pharmaceuticals | 2011-02-01 |
| A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB (NCT01125800) | Novartis Pharmaceuticals | 2011-02-01 |
| Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma (NCT01275209) | Novartis Pharmaceuticals | 2011-02-01 |
| Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (NCT01274351) | Novartis Pharmaceuticals | 2011-01-25 |
| A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (NCT01283516) | Novartis Pharmaceuticals | 2011-01-24 |
| A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD) (NCT01542866) | Novartis Pharmaceuticals | 2011-01-11 |
| Ranibizumab "Treat and Extend" in Diabetic Macular Edma (NCT01297569) | Novartis Pharmaceuticals | 2011-01-01 |
| Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension (NCT01237873) | Novartis Pharmaceuticals | 2011-01-01 |
| Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment (NCT01257815) | Novartis Pharmaceuticals | 2011-01-01 |
| A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People (NCT01259297) | Novartis Pharmaceuticals | 2011-01-01 |
| Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT01285492) | Novartis Pharmaceuticals | 2011-01-01 |
| Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload (NCT01459718) | Novartis Pharmaceuticals | 2011-01-01 |
| An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects (NCT01442259) | Novartis Pharmaceuticals | 2011-01-01 |
| Study of BGG492 in Patients With Chronic Subjective Tinnitus (NCT01302873) | Novartis Pharmaceuticals | 2011-01-01 |
| To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy (NCT01302899) | Novartis Pharmaceuticals | 2011-01-01 |
| Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload (NCT01254227) | Novartis Pharmaceuticals | 2011-01-01 |
| A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab (NCT01285466) | Novartis Pharmaceuticals | 2011-01-01 |
| A Global Imatinib and Nilotinib Pregnancy Exposure Registry (NCT01289054) | Novartis Pharmaceuticals | 2011-01-01 |
| An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension (NCT01281306) | Novartis Pharmaceuticals | 2011-01-01 |
| Drug Use Investigation for REVOLADE (ITP) (NCT01416311) | Novartis Pharmaceuticals | 2010-12-21 |
| A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma. (NCT01237236) | Novartis Pharmaceuticals | 2010-12-21 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients (NCT02675803) | Novartis Pharmaceuticals | 2010-12-20 |
| Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF) (NCT01148797) | Novartis Pharmaceuticals | 2010-12-01 |
| Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients (NCT01257451) | Novartis Pharmaceuticals | 2010-12-01 |
| Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients (NCT01375179) | Novartis Pharmaceuticals | 2010-12-01 |
| Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (NCT01266135) | Novartis Pharmaceuticals | 2010-12-01 |
| Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor (NCT01324492) | Novartis Pharmaceuticals | 2010-12-01 |
| Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia (NCT01979601) | Novartis Pharmaceuticals | 2010-12-01 |
| A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (NCT01235962) | Novartis Pharmaceuticals | 2010-11-30 |
| A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors (NCT01231594) | Novartis Pharmaceuticals | 2010-11-05 |
| GSK1120212 Rollover Study (NCT01376310) | Novartis Pharmaceuticals | 2010-11-02 |
| Efficacy, Safety, and Pharmacokinetics of QAW039 (NCT01253603) | Novartis Pharmaceuticals | 2010-11-01 |
| A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension (NCT01256411) | Novartis Pharmaceuticals | 2010-11-01 |
| CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib (NCT01227577) | Novartis Pharmaceuticals | 2010-11-01 |
| Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (NCT01263353) | Novartis Pharmaceuticals | 2010-11-01 |
| Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD) (NCT01259492) | Novartis Pharmaceuticals | 2010-11-01 |
| Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device. (NCT01262586) | Novartis Pharmaceuticals | 2010-11-01 |
| Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration (NCT01255462) | Novartis Pharmaceuticals | 2010-11-01 |
| The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients (NCT01250171) | Novartis Pharmaceuticals | 2010-11-01 |
| Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome (NCT01253629) | Novartis Pharmaceuticals | 2010-11-01 |
| Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease (NCT01302860) | Novartis Pharmaceuticals | 2010-11-01 |
| 1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids (NCT01197300) | Novartis Pharmaceuticals | 2010-10-25 |
| Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations (NCT01131325) | Novartis Pharmaceuticals | 2010-10-21 |
| Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF (NCT01392443) | Novartis Pharmaceuticals | 2010-10-14 |
| Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy (NCT01200589) | Novartis Pharmaceuticals | 2010-10-11 |
| A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene (NCT01219699) | Novartis Pharmaceuticals | 2010-10-05 |
| Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (NCT01217944) | Novartis Pharmaceuticals | 2010-10-01 |
| Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin (NCT01426802) | Novartis Pharmaceuticals | 2010-10-01 |
| Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections (NCT01232595) | Novartis Pharmaceuticals | 2010-10-01 |
| To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma (NCT01568762) | Novartis Pharmaceuticals | 2010-10-01 |
| Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS). (NCT01242813) | Novartis Pharmaceuticals | 2010-10-01 |
| A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors (NCT01106508) | Novartis Pharmaceuticals | 2010-10-01 |
| Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) (NCT01242774) | Novartis Pharmaceuticals | 2010-10-01 |
| An East Asian Study of LDE225 (NCT01208831) | Novartis Pharmaceuticals | 2010-10-01 |
| A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy. (NCT01124864) | Novartis Pharmaceuticals | 2010-10-01 |
| A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors (NCT01195376) | Novartis Pharmaceuticals | 2010-10-01 |
| Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. (NCT01066468) | Novartis Pharmaceuticals | 2010-10-01 |
| Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias (NCT01173731) | Novartis Pharmaceuticals | 2010-10-01 |
| Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis (NCT01201356) | Novartis Pharmaceuticals | 2010-09-13 |
| A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (NCT01202188) | Novartis Pharmaceuticals | 2010-09-01 |
| Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus (NCT01171976) | Novartis Pharmaceuticals | 2010-09-01 |
| Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy (NCT01202903) | Novartis Pharmaceuticals | 2010-09-01 |
| Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab (NCT01271920) | Novartis Pharmaceuticals | 2010-09-01 |
| Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis (NCT01185821) | Novartis Pharmaceuticals | 2010-08-30 |
| Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy (NCT01077518) | Novartis Pharmaceuticals | 2010-08-26 |
| Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients (NCT01114529) | Novartis Pharmaceuticals | 2010-08-09 |
| Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers (NCT01529294) | Novartis Pharmaceuticals | 2010-08-01 |
| An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints (NCT01216085) | Novartis Pharmaceuticals | 2010-08-01 |
| The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada (NCT01105507) | Novartis Pharmaceuticals | 2010-08-01 |
| An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age (NCT01151410) | Novartis Pharmaceuticals | 2010-08-01 |
| 24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients (NCT01169701) | Novartis Pharmaceuticals | 2010-08-01 |